Mantle cell lymphoma Trials in Baltimore, United States
Conditions / Mantle cell lymphoma / Baltimore, United States
Mantle cell lymphoma has been the subject of sustained clinical investigation across multiple research sites.
25 total trials for this combination
Showing top 10 of 25 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02952508 | Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | RECRUITING | — |
| NCT01000753 | Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma | COMPLETED | — |
| NCT01415752 | Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | TERMINATED | PHASE2/PHASE3 |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | COMPLETED | PHASE1 |
| NCT05458297 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | RECRUITING | — |